Atlas Trials

PRE-I-SPY Phase I/Ib Oncology Platform Program

Clinical trial NCT05868226 · RECRUITING

Trial details

NCT number
NCT05868226
Sponsor
QuantumLeap Healthcare Collaborative
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
HER2-positive Breast CancerMetastatic CancerMetastatic Breast CancerMetastaticHER2-positive Metastatic Breast CancerHER2 Mutation-Related TumorsHER-2 Protein OverexpressionHER2-negative Breast CancerTriple Negative Breast CancerHR PositiveHormone Receptor-positive Breast CancerEstrogen Receptor Positive Tumor
Start date
2023-02-15
Primary completion
2028-12-30
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.